Specifically, mesenchymal neuroblastomas were, as expected, less sensitive to standard-of-care treatments [3, 4], but unexpectedly more sensitive towards MEK inhibitors than the adrenergic subtype. This evidence concerns the gene MAP2K7 and neuroblastoma.